plerixafor has been researched along with Duncan Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anasetti, C; Bookout, RN; Fernandez, HF; Janssen, WE; Perkins, JB; Shapiro, JF; Yee, GC | 1 |
| Badel, K; Bridger, G; Calandra, G; Crocker, SA; Dye, A; Grove, B; McCarty, J; McGuirk, J; Tricot, G | 1 |
1 trial(s) available for plerixafor and Duncan Disease
| Article | Year |
|---|---|
AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Colony-Stimulating Factors; Cyclams; Drug Synergism; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Salvage Therapy; Transplantation, Autologous | 2008 |
1 other study(ies) available for plerixafor and Duncan Disease
| Article | Year |
|---|---|
Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cancer Care Facilities; Cyclams; Drug Costs; Drug Resistance; Drug Therapy, Combination; Female; Filgrastim; Florida; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Transplantation, Autologous | 2012 |